Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

PREPAID EXPENSES AND OTHER CURRENT ASSETS

v3.24.3
PREPAID EXPENSES AND OTHER CURRENT ASSETS
6 Months Ended
Jun. 30, 2024
Prepaid Expenses And Other Current Assets  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

The Company’s prepaid expenses and other current assets consist of the following:

 

    June 30, 2024     December 31, 2023  
Other receivables   £ 392     £ 51,584  
VAT owed to the Company     48,677       135,642  
Prepaid clinical trial costs     80,000       307,519  
Deferred clinical trial testing costs     1,177,500       1,177,500  
Other prepayments     381,300       522,480  
Total   £ 1,687,869     £ 2,194,725  

 

The fair value of trade and other receivables are not materially different to the book value.